Ablexis Announces Availability Of The AlivaMab Mouse Technology And Settlement Of The Litigation With Regeneron

SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC today announced the completion and delivery to its licensees of its AlivaMab Mouse technology, an innovative and unique platform for discovery of the next generation of breakthrough human antibody drugs. The delivery of the AlivaMab Mouse technology to licensees earlier in 2014 enabled their deployment of the technology broadly throughout their respective organizations, providing non-exclusive long-term access with no target or field of use limitations, and fulfilling the needs of these companies for an improved transgenic platform for therapeutic antibody discovery. The AlivaMab Mouse technology remains available for non-exclusive licensing and immediate delivery.

Help employers find you! Check out all the jobs and post your resume.